SMS Pharma Q1 PAT jumps 153% yoy to Rs23.6cr

Revenue grew by 44.4% yoy. Highest ever EBITDA margin at 27.3%, driven by better product mix and realisations, the company said.

August 10, 2021 4:49 IST | India Infoline News Service
SMS Pharmaceuticals Limited, a Hyderabad based diversified and fully integrated pharmaceutical company, with interests in Active Pharmaceutical Ingredients (API) and Intermediates announced its financial results for the quarter ended June 30, 2020.

The company’s revenue from operations stood at Rs163cr as against Rs112.9cr, up 44.4% yoy. EBITDA stood at Rs44.4cr as against Rs21.4cr yoy. EBITDA margin (%) came in at 27.3%. Profit After Tax (PAT) stood at Rs23.6cr as against Rs9.2cr yoy. PAT Margin (%) came in at 14.2%.

SMS Pharmaceuticals Ltd ended at Rs179.95 down per piece by Rs6.45 or 3.46% from its previous closing of Rs186.40 per piece on the BSE.

API Segment Highlights
  • Ql revenue for the API segment stood at Rs150.8cr, up 37% yoy.
  • API segment contributed approximately 93% to the consolidated revenue.
  • Within the API segment, ~34% of the revenues came from the domestic market and 66% from the exports market (including deemed exports) for Q1FY22.
  • Within the API segment, the anti-retroviral therapeutic category contributed around 43%, anti-viral around 15%, anti-epileptic around 11%, anti-migraine around 9%, anti-erectile dysfunction around 6% and the rest contributed around 16% to total API sales.
“Despite facing multiple 2nd wave of covid-19 induced challenges, the company registered a robust revenue growth of 44.4% on YoY basis, driven by strong volume growth. This robust performance is a testimony of company's agility, resilience and strong execution capabilities during these difficult times. Over the years, as a strategy, the company has focused on backward integration and maintaining the leadership position in the top therapeutic areas - anti-ulcer, ARV and anti-migraine. As a result, the company did not witness adverse impact of higher raw material prices and supply chain disruptions on the margins. Continuous efforts to invest in backward integration has reduced import dependency on China for raw materials and KSMs to a great extent. This coupled with China+ 1 strategy, is expected to drive a growth in exports significantly, going forward,” P. Vamsi Krishna, Executive Director - SMS Pharmaceuticals Limited, said.

The company has incurred a capex of Rs198cr in FY21. This capex was aimed towards capacity expansion at the Vizag plant. This capacity expansion will commercialize fully by the end of FY22 and expected to drive the next leg of growth. The growth trajectory in the API segment is expected to accelerate further in the upcoming quarters underpinned by company's leadership position in top therapies, strong demand and pick-up in the exports business,” he added.

FREE Benefits Worth 5,000



Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity